source
- Recon: FDA identifies four deaths in Newron schizophrenia drug trials; Dutch court blocks subcutaneous Keytruda in eight Europea...Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 13d ago↗ source
- Optogenetics therapy restores light sensitivity in half of retinitis pigmentosa patients in early trialA small clinical study examined an optogenetics‑based approach for treating retinitis pigmentosa, a genetic disorder that progressively destroys retinal light‑sensing cells and often leads to legal…